Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellipharmaceutics International Inc (OP:IPCIF)

0.1500 UNCHANGED
Last Price Updated: 10:52 AM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1500
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1500
Today's Range 0.1500 - 0.1500
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intellipharmaceutics Announces Downgrade to OTC Expert Market
Via ACCESSWIRE
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Via ACCESSWIRE

Performance

More News

Read More
Intellipharmaceutics Announces Cease Trade Order
Via ACCESSWIRE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Via ACCESSWIRE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Via ACCESSWIRE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Via ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2023 Results
Via ACCESSWIRE
Intellipharmaceutics Reports Director Election Results
Via ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2023 Results
Via ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2022 Results
Via ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Via ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2022 Results
Via ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2022 Results
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Reports Director Election Results
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Announces First Quarter 2022 Results
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Reports Director Election Results
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Comments on Recent Trading Activity
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Announces Third Quarter 2021 Results
From Intellipharmaceutics International Inc.
Via AccessWire
Topics Bankruptcy Intellectual Property
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
From Intellipharmaceutics International Inc.
Via AccessWire
Intellipharmaceutics Announces First Quarter 2021 Results
From Intellipharmaceutics International Inc.
Via AccessWire
Topics Bankruptcy Intellectual Property

Frequently Asked Questions

Is Intellipharmaceutics International Inc publicly traded?
Yes, Intellipharmaceutics International Inc is publicly traded.
What exchange does Intellipharmaceutics International Inc trade on?
Intellipharmaceutics International Inc trades on the OTC Traded
What is the ticker symbol for Intellipharmaceutics International Inc?
The ticker symbol for Intellipharmaceutics International Inc is IPCIF on the OTC Traded
What is the current price of Intellipharmaceutics International Inc?
The current price of Intellipharmaceutics International Inc is 0.1500
When was Intellipharmaceutics International Inc last traded?
The last trade of Intellipharmaceutics International Inc was at 07/02/24 10:52 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.